我认为迷幻蘑菇（裸盖菇，magic mushrooms）是一种长寿疗法。 在分析了两次给药的数据后，我发现裸盖菇素（psilocybin）展现出独特的长寿相关效应，这些效应与我迄今为止采用的、效果最好的疗法形成互补，包括：桑拿、高压氧疗法、睡眠、营养与运动。 这是有史以来量化程度最高的一次迷幻剂实验。 值得注意的是，尽管我的许多生物标志物已经处在人群中前 1% 的最优区间，裸盖菇素仍然显示出多系统的改善——这是其他疗法尚未做到的。 当然，这些数据仍需要被复制验证，其效果的幅度与持续时间也需要进一步评估。 我们学到的结论如下： 0. 我们观察到在心理、激素、代谢以及抗炎系统上的广泛益处。由于这些系统是生物衰老的主要驱动因素，这种多系统信号为其长寿潜力提供了有力证据。 1. 裸盖菇素可能是大脑的一个代谢重置按钮。我们预期会看到大脑变化，但没想到可能出现代谢层面的突破。我的血糖控制从人群前 2%改善到前 0.2%，优于 99.75% 的 18–25 岁人群。 2. 裸盖菇素在给药后一周内，将我的炎症指标（hsCRP）降低到检测不到的水平。 3. 裸盖菇素让我的身心状态变得更加平静。给药后的几天内，皮质醇下降，HPA 轴受到抑制。皮质醇与 DHEA（另一种肾上腺皮质激素）分别下降 42% 和 45%，表明与休息和恢复相关的整体肾上腺“重置”。 4. 裸盖菇素提高了大脑可塑性，使默认网络去同步化，带来更高的创造力、玩乐感和开放性，同时减少了心理僵化。 5. 第二次给药在第一次的基础上进一步增强效果，使感官整合程度超过第一次的峰值。 6. 裸盖菇素诱发了一种强烈的快乐、深刻的洞察与微妙的忧郁感的混合状态，这种状态也可通过热成像生物指标检测到。 本次实验有两个重要的首次： 0. 首次记录到基于 连续血糖监测（CGM） 的、裸盖菇素后血糖控制改善的人体观察结果。 1. 首次获得高剂量裸盖菇素体验的人体面部与身体热成像图谱。 待公布数据： * 端粒长度与端粒酶相对活性（端粒再生能力） * 表观遗传测量 * 肠道微生物组 实验细节 以下是我两次迷幻蘑菇体验、剂量以及目前测量结果的更多细节。 我在三周内服用了两次干燥并研磨的裸盖菇（Psilocybe cubensis，B+ 品种）。 第一次（11 月 9 日）：4.67 g（24.98 mg 裸盖菇素，3.5 mg 裸盖菇胺） 场景：较为私密，仅与 @_katetolo 及陪同向导在场 第二次（11 月 30 日）：5.35 g（28 mg 裸盖菇素，4 mg 裸盖菇胺） 场景：相对开放，朋友与家人通过线上参与，并进行直播 第一次我将剂量溶解在橙汁中，第二次改用柠檬汁，原因如下： 柠檬更酸，可延缓裸盖菇素向裸盖菇胺的转化与溶液中的分解，从而在摄入后保留更多可激活的裸盖菇素。 柠檬汁的糖分平均低 70%、热量低 45%，对我整体的空腹状态干扰更小，也带来了更低的血糖峰值。 大脑连接的重塑 第一次给药后的 Kernel Flow 测量显示，我的大脑连接变化与主观体验一致，并与 5-HT2A 受体的分布相吻合。 具体表现为： 默认网络与指挥中枢（包括前额叶语境处理）受到抑制 初级运动、感觉、听觉与语言网络之间的功能连接与超整合增强 这对应一种高熵大脑状态：更加开放、灵活、探索性更强、更具创造力，显示出从“老化与僵化”向“年轻与开放”状态的转变。 第二次给药前的基线测量显示，第一次给药在 3 周后仍有显著持续效应；第二次给药后的峰值测量显示出叠加效应，其感官-运动整合程度超过第一次峰值，尤其是听觉、语言与表达网络的激活增强，与我在亲友陪伴下更愿意表达和描述感受相一致。 面部与身体热成像生物指标 我们制作了首张迷幻蘑菇体验的人体面部与上半身热成像图谱。 核心体温上升 1.5–2°F，提示一次强烈的迷幻体验，可能与较高剂量（28 mg 裸盖菇素，总精神活性成分 32 mg）有关。 热量向核心重新分布，与 5-HT2A 介导的自主神经激活一致，在体验高峰及其后期持续存在。 面部与身体的热变化显示出强烈快乐、洞察与微妙忧郁的混合状态。 裸盖菇素后血糖控制的首次人体 CGM 证据 裸盖菇素似乎触发了此前未知的大脑代谢重置，这是一次意外的突破。 对比给药前后各 3 天的数据： 血糖控制显著改善，从人群前 2% 提升至前 0.2%（包括健康的 18–25 岁人群）。 平均血糖下降 8%，达到 80.84 mg/dL（个人新低）。 血糖波动下降 11%，峰值更平滑、控制更好。 单次体验使估算的 HbA1c 从 4.7% 降至 4.4%（相对下降 6.8%）。 持续性：第 3 天的效果与第 1 天同样显著。 （注：第 4 天前往中国的长途旅行打断了这一趋势，下一次给药将进一步评估持续时间。） 这很重要，因为目前我们用长期每日用药（如二甲双胍、胰岛素、GLP-1）来治疗糖尿病与代谢功能障碍。而这些数据提示：一次神经可塑性事件，可能对肝脏与胰腺产生下游效应，其效果可与这些药物相当甚至更强。 系统性炎症降至检测下限 第一次给药 5 天后，hsCRP 降至 检测不到（<0.15 mg/dL），较给药前 0.23 mg/dL 下降 35–100%。 第二次给药 3 天后，hsCRP 为 0.18 mg/dL，仍较基线下降 22%。 TNF-α 在基线与第二次给药后未见变化（第一次后未测）。 下一次给药将测量更广泛的炎症指标，包括 IL-6、IL-10，并覆盖多个给药后时间点。 峰值皮质醇升高，随后一周压力显著降低 急性高峰期，皮质醇显著升高； 随后一周，晨间皮质醇下降，HPA 轴受抑，符合“余晖期（after-glow）”的放松状态。 具体表现为： 服用后 4 小时，皮质醇达到晨峰的 3 倍； 入睡前恢复至正常夜间基线； 5 天后，晨间皮质醇下降 42%，DHEA-S 下降 45%，与肾上腺活动抑制一致； 雌二醇水平上升 200%，与初步研究中“外周 5-HT2A 激活通过促进芳香化酶表达而提高雌激素”的证据一致。 I think magic mushrooms are a longevity therapy. After seeing the data from two doses, psilocybin offers unique longevity effects that complement the best performing therapies I’ve done to date including sauna, hyperbaric oxygen therapy, sleep, nutrition and exercise. This was the most quantified psychedelic experiment ever done. It's noteworthy that even though many of my biomarkers are already in the 99th percentile optimal, psilocybin still showed multi-system improvements. Something other therapies have not been able to accomplish. Of course, my data will need to be replicated and the magnitude and duration of benefits needs further assessment. Here is what we learned: 0. We observed broad benefits across mental, hormonal, metabolic, and anti-inflammatory systems. Since these are the primary drivers of biological aging, this multi-system signal offers a compelling case for longevity potential. 1. Psilocybin may be a metabolic reset button for the brain. We expected brain changes, but not a potential metabolic breakthrough. My blood sugar control improved from the top 2% of the population to 0.2%, better than 99.75% of 18-25 year olds. 2. Psilocybin reduced my inflammation (hsCRP) to below detectable levels one week post dose. 3. Psilocybin calmed my body and mind. Lower cortisol, and an inhibited HPA-axis in the days following the dose. Both my cortisol and DHEA (another product of the adrenal cortex) dropped 42% and 45% respectively, indicating an overall adrenal reset associated with rest and recovery. 4. Psilocybin increased brain plasticity, desynchronized default networks, resulting in enhanced creativity, playfulness, and openness, with reduced mental rigidity. 5. A second psilocybin dose built on the first and pushed sensory integration even further, increasing primary sensory-motor integration beyond the peak of the first dose. 6. Psilocybin induced an intense blend of joy, deep insight, and a subtle hint of melancholy, also detectable by thermal biometrics. We had two significant firsts in this experiment: 0. First documented human CGM-based observation of improved post-psilocybin glucose control. 1. First-ever thermal profile of an intense psilocybin dose. Pending data: + Telomere length and relative telomerase activity (telomere regeneration capacity). + Epigenetic measurements + Microbiome Experiment details Here are more details about my two magic mushrooms trips, doses, and the results of my measurements up to date. I had two doses of dried and powdered Psilocybe Cubensis (Variety B+) mushrooms, three weeks apart. First dose Nov 9th: 4.67g (24.98 mg psilocybin and 3.5 mg psilocin). Setting: relatively private, only with @_katetolo and the accompanying guide. Second dose Nov 30th: 5.35 g (28 mg psilocybin and 4 mg psilocin). Setting: relatively open, with friends and family joining virtually, and live streaming. I dissolved the first dose in orange juice but used lemon juice for the second, for the following reasons: + Lemon is more sour, which delays the conversion to psilocin and breakdown in solution, thus preserving more total psilocybin to be activated to psilocin after ingestion. + Lemon juice has, on average, 70% less sugar and 45% less calories, making it less disruptive to my otherwise faster state throughout the journey, and leading to a much lower glucose peak. Rewired brain connectivity Kernel Flow measurements after the first dose showed shifts in my brain connectivity mirroring my subjective experience, and the mapping of 5-HT2A receptors. These included the inhibition of my default networks and command centers including prefrontal context and a shift towards increased functional connectivity and hyperintegration between primary motor, sensory, auditory, and speech integration. This coincided with an entropic brain pattern, more open, flexible, exploratory, and creative, indicating a shift from aged and rigid to open youthful brain state. The baseline measurement before the 2nd dose indicated a strong lasting effect from the first dose 3 weeks earlier, post-peak measurement after the 2nd dose indicated an additive effect of the 2nd dose, with a brain entropic and increased primary sensory-motor integration beyond the peak of the first dose. Most notable was the increased intensity of integration and activation of the auditory, speech, and language networks, coinciding with the second dose being joined by family, friends, where I enjoyed expressing and describing my feelings. Face and body thermal biometrics We produced the first ever face and upper body thermal map of a magic mushroom journey. A core temperature increase of 1.5–2°F suggests an intense psychedelic experience, likely due to a large psilocybin dose (28 mg psilocybin, 32 mg combined psychoactive content). Heat was redistributed to the core, consistent with 5HT2A–mediated autonomic activation, which can include increased sympathetic tone, lasting through the peak and early post-peak of the experience. Facial and body thermal shifts indicate a potential blend of intense joy, insight, and subtle sadness or melancholy. First documented human CGM-based observation of improved post-psilocybin glucose control Psilocybin appears to have triggered a previously unknown metabolic reset in my brain, an unexpected breakthrough. Comparing the 3-day periods before and after the psilocybin dose: My blood glucose control dramatically improved, moving from the top 2% to the top 0.2% of the entire population, including healthy 18-25 year olds. + 8% reduction in mean blood glucose, reaching 80.84 mg/dL, a new personal best. + 11% reduction in fluctuation, indicating smoother glucose peaks and improved control. + This single session reduced my estimated HbA1c 0.3 6.8% from 4.7% to 4.4%, (a relative reduction of 6.8%). + Durability: The positive effect was still as strong on Day 3 post-dose as it was on Day 1. Note: A long trip to China on Day 4 interrupted this streak. We plan to explore the full durability of this effect with the next dose. This matters because we treat diabetes and metabolic dysfunction with chronic daily medication (Metformin, Insulin, GLP-1s). This data suggests that a neuroplastic event might have downstream effects on the liver and pancreas that mimic or exceed these drugs. Systemic inflammation was below detectable levels Five days after the first dose, my hsCRP dropped to an undetectable level (below 0.15 mg/dL), representing a 35-100% decrease from the pre-dose level of 0.23 mg/dL. Three days post-second dose, hsCRP was barely detectable at 0.18 mg/dL, which is still a 22% drop from the initial baseline. Tumor necrosis factor-alpha (TNF-alpha) remained unchanged between baseline and post-second dose. It was not measured after the first dose. For the next dose, we will measure a wider panel of inflammatory markers, including IL-6 and IL-10, and cover several time points post-dose. High cortisol at Peak, low cortisol and stress the following week Cortisol spiked at the peak of the acute phase, followed by a decline in morning cortisol levels and HPA-axis inhibition, consistent with a relaxed "after-glow" phase in the week following the trip. My cortisol spiked to 3x morning spike levels four hours after taking the mushroom dose. Levels returned to normal nightly baseline before bedtime. Five days post-dose, my morning cortisol levels had dropped by 42%, and DHEA-S (a marker of adrenal activity) also dropped by 45%, aligning with inhibited HPA-axis and adrenal activity. Estradiol levels increased by 200%, consistent with preliminary published evidence that peripheral 5HT2A activation increases cortisol by driving aromatase expression.